On March 18, 2026 Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, reported that Seth Lederman, MD, Chief Executive Officer, will deliver a company presentation at BIO-Europe Spring 2026, being held March 23-25, 2026, in Lisbon, Portugal.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Company Presentation Details

Date and Time: Tuesday, March 24, 2026, 1:30-1:45 p.m. WET
Location: Presentation Theatre A
Presenter: Seth Lederman, MD, Chief Executive Officer

(Press release, TONIX Pharmaceuticals, MAR 18, 2026, View Source [SID1234663705])

On March 18, 2026 Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, reported the company and its research collaborators will present 28 abstracts, including 3 oral sessions, showcasing advances in methylation-based tumor classification and liquid biopsy technology at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting in San Diego, California taking place April 17 – 22, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Key data that will be presented include:

An oral presentation of research data showing high accuracy of Guardant360 Tissue in determining tissue of origin with strong performance in cancers of unknown primary, correctly identifying the likely origin in approximately 92% of known cases across more than 6,000 tissue samples and 24 tumor types and supporting the clinical utility of methylation-based tumor typing for tissue samples in diagnostically challenging settings.
An oral presentation showcasing the expanded utility of Guardant360 Liquid beyond basic genomic testing, highlighting the strength of its novel epigenomic features in increasing clinical actionability. Researchers found that Guardant360 Liquid demonstrated actionable findings for 85% of metastatic breast cancer patients and 89% of patients with advanced colorectal cancer.
A real-world analysis evaluating the utility of Guardant Reveal to identify new primary malignancies during minimal residual disease (MRD) monitoring, demonstrating the potential to detect separate primary cancers in patients over time with non-invasive, liquid biopsy technology.
Additional research bolstering the potential of Guardant360 Tissue in expanding access to targeted treatment options showing that a tissue-based genomic instability score (GIS) can accurately detect DNA repair deficiencies in breast, ovarian, and pancreatic cancers and accurately identifying patients who may benefit from PARP inhibitors.
"The breadth of the data Guardant will be presenting demonstrate the power of our blood- and tissue-based tests in helping address critical gaps across cancer care," said Dr. Craig Eagle, Chief Medical Officer at Guardant Health. "From identifying cancers of unknown primary and detecting new malignancies in tandem with MRD monitoring to expanding treatment options for more cancers, we are eager to present these findings along with our research collaborators at the AACR (Free AACR Whitepaper) meeting and proud to offer innovative tests that are meeting today’s most complex challenges in cancer care."

Key Guardant Health and collaborator presentations at AACR (Free AACR Whitepaper) 2026

Presentation

Title

Time / Location

Monday, April 19

1316

A methylation-based molecular tumor typing classifier for tissue samples from cancers of unknown primary

April 19, 2026 / 3:00 PM – 5:00 PM PT

Tuesday, April 20

4016

Tissue-based homologous recombination deficiency status prediction in patients with breast, ovarian, and pancreatic cancers

April 20, 2026 / 2:30 PM – 4:30 PM PT

2279

DNA methylation-based classifier predicts SERD benefit in ESR1 wild-type HR+/HER2- breast cancer

April 20, 2026 / 9:00 AM – 12:00 PM PT

Poster hall / Section 34

Wednesday, April 21

6512

Exploring clinical actionability of expanded liquid biopsy in advanced breast and colorectal cancers

April 21, 2026 / 2:00 PM – 5:00 PM PT

Poster Section 43

6512

Evaluating molecular tumor type predictions for identifying new primary malignancies – A real-world clinical genomics analysis

April 21, 2026 / 2:00 PM – 5:00 PM PT

Poster Section 43

CT230

STRIDE regimen of tremelimumab and durvalumab as non-operative management strategy of MSI-H resectable gastric or gastroesophageal junction adenocarcinoma (GAC/GEJAC): final results of the cohort 2 of INFINITY study by GONO GI

April 21, 2026 / 10:15 AM – 12:15 PM PT

The full abstracts for Guardant Health and a list of all abstracts being presented at the AACR (Free AACR Whitepaper) Annual Meeting can be found here.

About Guardant360

Guardant360 Liquid is a blood-based test that analyzes tumor DNA fragments circulating in the blood (cfDNA) to identify genetic mutations in advanced solid tumors, helping oncologists find targeted therapies. It offers an alternative to tissue biopsies, providing comprehensive genomic profiling (CGP) to guide personalized treatment for a wide range of solid cancers including lung, breast, colorectal, and prostate cancer. Guardant360 Liquid is guideline-complete across all advanced solid tumors, and has been clinically validated in more than 1,500 publications and research abstracts.

About Guardant Reveal

Guardant Reveal is a tissue-free liquid biopsy test that detects minimal residual disease (MRD) and monitors recurrence in early-stage colorectal, breast, and lung cancers, helping oncologists guide treatment decisions. In addition to MRD detection, Reveal can be used for late-stage therapy response monitoring for patients with solid tumors. Guardant Reveal therapy response monitoring can be initiated at any time during a patient’s treatment journey, offering clinicians flexibility and actionable insights.

The first clinical-validation study of pan-cancer chemotherapy monitoring published in The Journal of Liquid Biopsy showed that Guardant Reveal predicts long-term patient benefit up to 18 months earlier than standard clinical measures.

(Press release, Guardant Health, MAR 18, 2026, View Source [SID1234663721])

On March 18, 2026 TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, reported the publication of preclinical research evaluating Pressure-Enabled Drug Delivery (PEDD) of nelitolimod in liver tumor models in Frontiers in Oncology.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The study evaluated the delivery and biologic activity of nelitolimod, an investigational Toll-like receptor 9 (TLR9) agonist, when administered using PEDD, compared with conventional delivery approaches. The research examined therapeutic distribution in a porcine liver tumor model and anti-tumor activity in murine liver metastasis models.

Key findings from the study include:

Improved intratumoral delivery: PEDD administration with the TriNav Infusion System resulted in significantly greater distribution of nelitolimod within and around tumors compared with delivery through a conventional microcatheter in an Oncopig model of hepatic tumors
Evidence of enhanced immune activity: Treatment using PEDD was associated with reduced levels of immunosuppressive myeloid-derived suppressor cells (MDSCs) and increased infiltration of cytotoxic CD8+ T cells within the tumor microenvironment.
Reduced tumor growth: In a murine liver metastasis model, nelitolimod delivered using PEDD significantly reduced tumor growth compared with systemic administration at key time points during the study.
Potential impact of delivery on immunotherapy performance: The findings support the concept that improving therapeutic distribution within tumors may influence both immune activation and anti-tumor activity.

"This study highlights the critical role that delivery plays in determining how effectively therapies engage the tumor microenvironment, particularly for immunotherapies designed to activate local immune responses," said Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences. "By combining PEDD-enabled delivery with nelitolimod, we observed improved distribution within tumors along with encouraging signals of immune activation and anti-tumor activity in these preclinical models. Importantly, these findings illustrate the broader potential of PEDD as a delivery platform capable of enhancing the intratumoral delivery of multiple therapeutic modalities while limiting exposure healthy tissue. We believe this approach may help unlock the full potential of immunotherapies and other agents for patients with difficult-to-treat solid tumors, including those in the liver."

For TriSalus Life Sciences, the data reinforces the Company’s strategy of combining PEDD-enabled delivery with locoregional immunotherapy approaches. The TriNav Infusion System is designed to temporarily overcome elevated intratumoral pressure and reopen collapsed microvasculature to promote distribution of therapeutics within tumors and surrounding tissue and increasing the level of the therapeutic in the tumor.

Nelitolimod is being investigated by TriSalus for use as an immunotherapy intended to stimulate immune responses within tumors. This study’s findings support continued investigation of approaches that combine targeted drug delivery with immune activation in solid tumors.

(Press release, TriSalus Life Sciences, MAR 18, 2026, View Source [SID1234663722])

On March 18, 2026 Inocras, a bioinformatics-led precision health company harnessing the power of whole-genome sequencing (WGS) data and proprietary analytics, and the Broad Institute reported the upcoming release of key insights from whole-genome analysis of over 8,000 public cancer whole genomes. This analysis aims to deliver one of the largest genome-wide landscapes of somatic mutations across human pan-cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"NCI’s public The Cancer Genome Atlas (TCGA) efforts have been central to many advances in cancer genomics, yet most of that progress has come from looking at a small portion of the genome," said Gad Getz, PhD, a professor of pathology at Harvard Medical School, Director of Bioinformatics at the Krantz Family Center for Cancer Research and Dept. of Pathology at Massachusetts General Hospital and Core Institute Member at Broad Institute of MIT and Harvard. Joining him as a co-lead of the Broad–Inocras collaboration, Esther Rheinbay, PhD, Assistant Professor of Medicine at Harvard Medical School and Massachusetts General Hospital Cancer Center and Associate Member at the Broad Institute of MIT and Harvard, added: "While genomic discovery has long centered on protein-coding genes, the vast ‘dark matter’ of the non-coding genome holds important clues to tumorigenesis. By looking at non-coding regulatory sequences, we are identifying candidate driver events that were previously missed by standard sequencing approaches". Dr. Getz further noted, "By providing a harmonized, high-quality whole-genome variant dataset across thousands of samples, this collaboration creates a standard reference for cancer whole genome studies that can uncover novel coding and non-coding driver events as well as new potential targets; moreover, it can be used to train next-generation AI and other computational models poised to reveal new insights and transform precision oncology".

Whole-genome sequencing is the next step for genomic discovery

Broad Institute and Inocras researchers teamed up to analyze thousands of high-quality whole cancer genomes released by NCI for the TCGA project. This dataset is the landmark cancer genomics program of the NCI that has molecularly characterized over 8,000 cases across 31 different cancer types with well-annotated clinical information and has been an invaluable resource for cancer research and for developing cancer diagnostics tools for nearly two decades. However, previous studies have been limited, relying primarily on whole-exome sequencing data analysis, leaving several key aspects understudied, including oncogenic driver mutations in non-coding regions, genomic rearrangements (structural variations; SVs), genome-wide copy number alterations (CNA), and mutational signatures. As a consequence, most routine cancer sequencing and discovery work has thus far relied on targeted gene panels that cover only a small fraction of the genome.

A harmonized dataset for cancer whole genomes

The Broad–Inocras collaboration moves the field to whole-genome coverage at scale: The whole genome analysis was performed using a bioinformatics pipeline by the Broad Institute and CancerVisionTM from Inocras in parallel, and then the two organizations harmonized the variant calls for the downstream analysis. All the data was consolidated into a single, frozen, and well-curated dataset to enable a consistent analysis across both groups and robust benchmarking of computational and AI methods. This effort represents a unified whole genome analytical framework for the TCGA dataset, establishing a new gold standard for cancer genome research.

"The powerful cancer whole genome pipelines of both organizations at production scale have made this project possible, while creating a robust tumor-normal whole genome cancer dataset," said Dr Young Seok Ju, Co-Founder of Inocras, Director of Genome Insight Institute and Associate Professor at KAIST. " The whole genome pipelines and dataset set the gold standard of cancer research, potentially unlocking the next wave of cohort studies, drug discovery, and AI-driven cancer research at a WGS level."

AACR Annual meeting 2026 sessions to present results from the Broad–Inocras collaboration and future initiatives

The key insights from this collaboration will be shared in different forums and poster sessions during the AACR (Free AACR Whitepaper) Annual Meeting 2026. Prof. Getz from the Broad Institute will present "New Insights from TCGA Whole-Genome Sequencing" during the Educational Session on Saturday, April 18th. In addition, the principal investigators from the Broad Institute and Inocras—including Prof. Getz; Dr. Rheinbay; and Youngseok Ju, MD, PhD, Co-founder of Inocras and Associate professor at the Korea Advanced Institute of Science and Technology—will jointly present data highlights and discuss future initiatives during the Exhibitor Spotlight session "TCGA and Beyond: Whole-Genome Data Powering the Next Era of Cancer Intelligence" on Monday, April 20th.

(Press release, Broad Institute of Harvard and MIT, MAR 18, 2026, View Source [SID1234663723])

On March 18, 2026 AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company") reported that the Japan Patent Office has fully approved a Japanese patent covering the Company’s proprietary use of Ampligen (rintatolimod) in combination with checkpoint inhibitors (anti-PD-1 or anti-PD-L1 antibodies) for the treatment of cancer. The patent was granted in September 2025, but had to then pass a 6-month opposition period. Japan is one of the largest health markets in the world, with Japan and the United States expected to experience the greatest increase in global pancreatic cancer burden by 2030. The Japan patent expires December 20, 2039.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The allowed claims in Japan cover an agent for treating cancer consisting of Ampligen in combination with a checkpoint inhibitor. The claims are broad and encompass multiple cancer types – including pancreatic cancer. AIM also holds a U.S. patent (expires August 9, 2039) for methods involving the use of Ampligen as part of a combination oncology therapy when paired with an anti-PD-L1 antibody and a patent in the Netherlands (expires December 19, 2039) for the use of Ampligen as a combination cancer therapy with checkpoint blockade inhibitors, such as Keytruda (pembrolizumab), Opdivo (nivolumab) and Imfinzi (durvalumab).

AIM CEO Thomas K. Equels stated: "AIM is committed to developing Ampligen for the treatment of late-stage pancreatic cancer, which is an extremely lethal and unmet global health problem. Securing this critical patent in a key global market is just the latest step in AIM’s robust development and commercialization strategy."

AIM also intends to expand its intellectual property portfolio by pursuing orphan drug designation in Japan for Ampligen in the treatment of pancreatic cancer. The Company already holds Orphan Drug designations for pancreatic cancer in the United States and the European Union. While the details of the designations vary by region, the purpose is to incentivize the development of therapies for unmet health needs, by providing various benefits and market exclusivity after a drug receives market approval.

(Press release, AIM ImmunoTech, MAR 18, 2026, View Source [SID1234663692])